Saccharopolyspora erythraea with reduced emission of isoolfactory compounds as well as genetic modification method and application thereof

By knocking out the teroporin and 2-methyl isobornase synthase genes in red sugar polysporin, the genetically engineered strain was constructed, and the problem of emission of isool compounds during the fermentation of red sugar polysporin was solved, and erythromycin was achieved Maintaining output and quality and reducing waste gas treatment costs.

CN119060923APending Publication Date: 2024-12-03SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310649956.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The isool compounds earth odorin and 2-methyl isoborne produced during the fermentation of red sugar polysporidium cause odor problems, which are difficult to effectively degrade in the existing technology, and genetic modification strategies are mainly focused on increasing erythromycin production rather than reducing emissions Exhaust gas.

Method used

Genetically engineered strains were constructed to block the production of these isool compounds by knocking out the terrestrialin synthase genes (SACE_3187, SACE_4907, SACE_3977) and 2-methylisobornase synthase genes (SACE_3722). Homologous recombination mechanism is used to construct engineered strains with gene deletion or insertion inactivated genes to ensure that the erythromycin fermentation yield and quality are not affected.

Benefits of technology

It successfully reduces the emission of isool compounds, reduces the cost of erythromycin fermentation waste gas treatment, provides environmental and economic benefits, and achieves directional blockade of the production of isool substances.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004264791670000221
    Figure BDA0004264791670000221
  • Figure BDA0004264791670000231
    Figure BDA0004264791670000231
  • Figure BDA0004264791670000241
    Figure BDA0004264791670000241
Patent Text Reader

Abstract

The invention provides Saccharopolyspora erythraea capable of reducing emission of isoolfactory compounds as well as a genetic modification method and application of the Saccharopolyspora erythraea, particularly, the expression level of endogenous geosmin synthase genes and / or 2-methylisoborneol synthase genes in an engineering strain is reduced, and compared with an original strain, the expression level of the endogenous geosmin synthase genes and / or the expression level of 2-methylisoborneol synthase genes is reduced. The production of geosmin and / or 2-methylisoborneol can be blocked, and the fermentation yield and quality of erythromycin are not influenced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology engineering, and in particular to a saccharopolyspora erythrae with reduced emission of odorous compounds, and a genetic modification method and use thereof.

[0002] background

[0003] Saccharopolyspora erythraea is the erythromycin-producing bacterium, originally isolated from the soil of the Philippine Islands. Eli Lily Company has successfully developed erythromycin A as the first generation of erythromycin by strain improvement, large-scale fermentation and product separation of Saccharopolyspora erythraea. The second and third generations of erythromycin synthesized with erythromycin A as a precursor have a wide range of clinical applications. my country is the world's largest producer and exporter of erythromycin. For the erythromycin industry with an annual output of nearly 10,000 tons, the discharge of "three wastes" of wastewater, waste gas and waste residue caused by large-scale fermentation production needs to be solved urgently.

[0004] Geosmin and 2-methylisoborneol are widely found in actinomycetes, cyanobacteria, myxobacteria, and fungi, and are believed to be closely related to the odors produced by the above microorganisms. As highly volatile odorous compounds, geosmin and 2-methylisoborneol will cause odors at extremely trace levels, and may directly lead to the outbreak of odor problems after entering the air and water bodies with the material cycle in nature. In terms of chemical structure, geosmin and 2-methylisoborneol both have stable saturated tertiary alcohol structures, and it is difficult to effectively achieve the degradation of the two by conventional methods such as adding hydrogen peroxide and ultraviolet light irradiation.

[0005] Compared with degrading pollutants after they are produced, blocking the biosynthesis of geosmin and 2-methylisoborneol can prevent the production of pollutants at the source. However, there has been no systematic study on the production of geosmin and 2-methylisoborneol by fermentation of Saccharopolyspora erythraea, nor has there been any report on engineered strains of Saccharopolyspora erythraea with reduced emissions of odorous compounds.

[0006] Moreover, most of the genetic modification strategies to date have been based on the perspectives of increasing erythromycin fermentation yield and optimizing components, but rarely on reducing fermentation waste gas emissions.

[0007] Therefore, there is an urgent need in the art to develop genetically stable Saccharopolyspora erythraea with reduced emission of odorous compounds, as well as a genetic modification method with good repeatability and operability for constructing related engineering strains. Summary of the invention

[0008] The purpose of the present invention is to provide a genetically stable Saccharopolyspora erythraea with reduced emission of odorous compounds, and a genetic modification method with good repeatability and strong operability for constructing related engineering strains.

[0009] Another object of the present invention is to provide Saccharopolyspora erythraea with reduced odorous compound emission.

[0010] Another object of the present invention is to provide a genetic modification method of the erythraea.

[0011] Another object of the present invention is to provide the use of the erythraea Saccharopolyspora and its genetic modification method.

[0012] In the first aspect of the present invention, a genetically engineered strain for blocking the production of geosmin and / or 2-methylisoborneol is provided, wherein the expression level of endogenous geosmin synthase gene and / or 2-methylisoborneol synthase gene in the engineered strain is reduced, the geosmin synthase gene includes SACE_3187, SACE_4907 and SACE_3977 genes, and the 2-methylisoborneol synthase gene is SACE_3722 gene.

[0013] In another preferred embodiment, the starting strain of the engineered strain is Saccharopolyspora erythraea.

[0014] In another preferred embodiment, the starting strain of the engineered strain is selected from the following group: Saccharopolyspora erythraea NRRL 2238, Saccharopolyspora erythraea HL3168 E3, or derivative strains thereof.

[0015] In another preferred embodiment, the engineered strain is Saccharopolyspora erythraea.

[0016] In another preferred embodiment, the genetically engineered strain is a bacterium of the class Actinomycetes.

[0017] In another preferred embodiment, the genetically engineered strain is a bacterium of the genus Saccharopolyspora.

[0018] In another preferred embodiment, the genetically engineered strain is a derivative strain of Saccharopolyspora erythraea NRRL 2238, preferably, Saccharopolyspora erythraea D3187-4907-3977, Saccharopolyspora erythraea D3722 or Saccharopolyspora erythraea D3187-4907-3977-3722.

[0019] In another preferred embodiment, the genetically engineered strain is a derivative strain of Saccharopolyspora erythraea HL3168 E3, preferably, Saccharopolyspora erythraea E3D3187-4907-3977-3722.

[0020] In another preferred embodiment, the reduced expression level of the endogenous geosmin synthase gene means that compared with the starting strain, the expression level of the geosmin synthase gene in the engineered strain is reduced by at least 30%, preferably by at least 60%, 70%, 80%, 90% or 100%.

[0021] In another preferred embodiment, the reduced expression level of the endogenous 2-methylisoborneol synthase gene means that compared with the starting strain, the expression level of the 2-methylisoborneol synthase gene in the engineered strain is reduced by at least 80%, preferably by at least 90% or 100%.

[0022] In another preferred embodiment, the geosmin synthase gene is derived from bacteria, preferably from the genus Saccharopolyspora, and most preferably from Saccharopolyspora erythrae.

[0023] In another preferred embodiment, the 2-methylisoborneol synthase gene is derived from bacteria, preferably from the genus Saccharopolyspora, and most preferably from Saccharopolyspora erythrae.

[0024] In another preferred example, the sequence of the SACE_3187 gene is shown in SEQ ID NO.1.

[0025] In another preferred example, the sequence of the SACE_4907 gene is shown as SEQ ID NO.2.

[0026] In another preferred example, the sequence of the SACE_3977 gene is shown in SEQ ID NO.3.

[0027] In another preferred example, the sequence of the SACE_3722 gene is shown as SEQ ID NO.4.

[0028] In another preferred embodiment, when the expression of three genes, SACE_3187, SACE_4907 and SACE_3977, is blocked at the same time, the genetically engineered strain no longer ferments to produce geosmin.

[0029] In another preferred embodiment, when the expression of the SACE_3722 gene is blocked, the genetically engineered strain no longer ferments and produces 2-methylisoborneol.

[0030] In another preferred embodiment, when the expression of four genes, namely, SACE_3187, SACE_4907, SACE_3977 and SACE_3722, is blocked at the same time, the genetically engineered strain no longer produces geosmin and 2-methylisoborneol by fermentation.

[0031] The second aspect of the present invention provides a method for constructing the engineered strain described in the first aspect of the present invention, comprising the steps of:

[0032] (a) reducing the expression level of endogenous geosmin synthase gene and / or 2-methylisoborneol synthase gene in the starting strain, thereby obtaining the engineered strain according to the first aspect of the present invention, wherein the geosmin synthase gene includes SACE_3187, SACE_4907 and SACE_3977 genes, and the 2-methylisoborneol synthase gene is SACE_3722 gene.

[0033] In another preferred embodiment, the method comprises the following steps:

[0034] (a1) knocking out the endogenous geosmin synthase gene and / or 2-methylisoborneol synthase gene in the host cell;

[0035] (b1) culturing the host cell.

[0036] The third aspect of the present invention provides a use of the engineered strain described in the first aspect of the present invention, wherein the engineered strain is used as a strain for (i) blocking the production of geosmin and / or 2-methylisoborneol; and (ii) fermenting and producing erythromycin.

[0037] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 It is the biosynthetic pathway of geosmin and 2-methylisoborneol.

[0039] Figure 2 These are the maps of gene insertion inactivation plasmids pOJ260-S3187, pOJ260-S4907, pOJ260-S3977, and pOJ260-S3722.

[0040] Figure 3 This is a schematic diagram of the genotypes of the single-gene insertion-inactivation engineered strains of Saccharopolyspora erythraea, S3187, S4907, S3977, and S3722, with S3187 used as an example to illustrate its construction strategy.

[0041] Figure 4 The maps are of the gene in-frame deletion plasmids pOJ260-D3187, pOJ260-D4907, pOJ260-D3977, and pOJ260-D3722.

[0042] Figure 5 This is a schematic diagram of the genotypes of the single-gene in-frame deletion engineered strains D3187, D4907, D3977, and D3722 of Saccharopolyspora erythraea, with D3187 used as an example to illustrate its construction strategy.

[0043] Figure 6 Maps of CRISPR / Cas9-mediated gene in-frame deletion plasmids pWHU2653-D3187, pWHU2653-D3977, and pWHU2653-D3722.

[0044] Figure 7 The following is a strategy for constructing a multi-gene in-frame deletion engineered strain of Saccharopolyspora erythraea, using D3187-4907-3977-3722 as an example.

[0045] Figure 8 This is the spore growth status of the starting strains NRRL 2238, HL3168 E3 and the engineered strains D3187-4907-3977-3722, E3D3187-4907-3977-3722 after being cultured on slant medium at 34°C for 7 days.

[0046] Fig. 9 The GC-MS / MS test results of the starting strain of Saccharopolyspora erythraea NRRL 2338 are shown, showing the TIC chromatogram and EIC chromatogram.

[0047] Fig.10 The GC-MS / MS test results of the production of geosmin by fermentation of a single gene knockout engineered strain of Saccharopolyspora erythrae show an EIC chromatogram with an extracted mass-to-charge ratio of 112. i, EIC chromatogram of the fermentation product of S3187; ii, EIC chromatogram of the fermentation product of D3187; ii, EIC chromatogram of the fermentation product of S4907; iv, EIC chromatogram of the fermentation product of D4907; v, EIC chromatogram of the fermentation product of S3977; vi, EIC chromatogram of the fermentation product of D3977; vii, EIC chromatogram of the fermentation product of S3722; viii, EIC chromatogram of the fermentation product of D3722.

[0048] Fig.11 The GC-MS / MS test results of the fermentation of 2-methylisoborneol by a single gene knockout engineered strain of Saccharopolyspora erythrae show an EIC chromatogram with an extracted mass-to-charge ratio of 95. i, EIC chromatogram of the fermentation product of D3187; ii, EIC chromatogram of the fermentation product of D4907; iii, EIC chromatogram of the fermentation product of D3977; iv, EIC chromatogram of the fermentation product of S3722; v, EIC chromatogram of the fermentation product of D3722.

[0049] Fig.12The GC-MS / MS test results of the fermentation of geosmin by the multi-gene knockout engineering strain of Saccharopolyspora erythraea show the EIC chromatogram with an extracted mass-to-charge ratio of 112. i, EIC chromatogram of the fermentation product of D3187-4907; ii, EIC chromatogram of the fermentation product of D3187-3977; iii, EIC chromatogram of the fermentation product of D4907-3977; iv, EIC chromatogram of the fermentation product of D3187-4907-3977; v, EIC chromatogram of the fermentation product of D3187-4907-3977-3722; vi, EIC chromatogram of the fermentation product of E3D3187-4907-3977-3722. DETAILED DESCRIPTION

[0050] After extensive and in-depth research and a large number of screenings, the inventors unexpectedly found that if the endogenous geosmin synthase genes (such as SACE_3187, SACE_4907 and SACE_3977 genes) and / or 2-methylisoborneol synthase genes (such as SACE_3722 genes) are knocked out in the starting strain, the production of geosmin and / or 2-methylisoborneol can be blocked, and the erythromycin fermentation yield and quality are not affected. Specifically, the present invention locates three geosmin synthase genes SACE_3187, SACE_4907, SACE_3977 and one 2-methylisoborneol synthase gene SACE_3722 in the genome of Saccharopolyspora erythrae through gene sequence comparison, and uses homologous recombination mechanism to construct an engineered strain with the above genes deleted or inserted inactivated in the same frame. It was unexpectedly discovered that knocking out the three genes SACE_3187, SACE_4907, and SACE_3977 at the same time can block the production of geosmin; knocking out the SACE_3722 gene can block the production of 2-methylisoborneol; knocking out the four genes SACE_3187, SACE_4907, SACE_3977, and SACE_3722 at the same time can block the production of geosmin and 2-methylisoborneol. The series of erythromycin engineering strains thus obtained can reduce the emission of odorous compounds without affecting the yield and quality of erythromycin, and help control the cost of erythromycin fermentation waste gas treatment. On this basis, the inventors completed the present invention.

[0051] the term

[0052] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0053] As used herein, when used in reference to a specific recited numerical value, the term "about" means that the value may vary by no more than 5% from the recited value. For example, as used herein, the expression "about 100" includes all values ​​between 95 and 105 (e.g., 95.1, 104.9, etc.).

[0054] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".

[0055] As used herein, the terms "above" and "below" include the number itself, for example, "above 20%" means ≥ 20%, and "above 8:1" means ≥ 8:1.

[0056] As used herein, "inactivation" means that the gene in question no longer expresses a functional protein. The modified DNA region is unable to naturally express the gene due to the deletion of part or all of the gene sequence, the shift of the gene reading frame, the introduction of missense / nonsense mutations, or the modification of the adjacent region of the gene, including sequences that control gene expression, such as promoters, enhancers, attenuators, ribosome binding sites, etc. Preferably, the target gene is inactivated by the deletion of part or all of the gene sequence, for example by gene knockout.

[0057] The presence or integrity of a gene on a bacterial chromosome can be detected by common methods such as PCR and Southern blotting. The amount of mRNA transcribed from a gene can be assessed by common methods such as Northern blotting and quantitative RT-PCR. The amount of protein encoded by a gene can be determined by common methods such as SDS-PAGE and Western blotting.

[0058] Explanation of symbols

[0059] SACE_3187 is a gene encoding geosmin synthase in the genome of Saccharopolyspora erythraea (GenBank: AM420293.1), and its sequence is shown in SEQ ID NO.1. Its encoded product is geosmin synthase (GenBank: WP_009945636.1).

[0060] SACE_4907 is a gene encoding geosmin synthase in the genome of Saccharopolyspora erythraea (GenBank: AM420293.1), and its sequence is shown in SEQ ID NO.2. Its encoded product is geosmin synthase (GenBank: WP_009948856.1).

[0061] SACE_3977 is a gene encoding geosmin synthase in the genome of Saccharopolyspora erythraea (GenBank: AM420293.1), and its sequence is shown in SEQ ID NO.3. Its encoded product is geosmin synthase (GenBank: WP_009944753.1).

[0062] SACE_3722 is a gene encoding 2-methylisoborneol synthase in the genome of Saccharopolyspora erythrae (GenBank: AM420293.1), and its sequence is shown in SEQ ID NO.4. Its encoded product is 2-methylisoborneol synthase (GenBank: WP_011874125.1).

[0063] SEQ ID NO.1:

[0064]

[0065] SEQ ID NO.2:

[0066]

[0067] SEQ ID NO.3:

[0068]

[0069] SEQ ID NO.4:

[0070]

[0071] Starting strain

[0072] As used herein, the term "starting strain of the present invention" refers to Saccharopolyspora erythraea numbered NRRL 2338 or HL3168 E3. The starting strain NRRL 2338 of the present invention is stored in the Agricultural Research Culture Collection (NRRL) of the United States and is numbered NRRL 2338. Another starting strain HL3168 E3 of the present invention is a derivative strain of NRRL2338, which is obtained by industrial strain screening and can ferment high-yield erythromycin [Appl.Environ.Microbiol.2011,77,7508]. It should be understood that the starting strain includes not only the strain numbered NRRL 2338 or HL3168 E3, but also its derivative strains.

[0073] Engineered strains

[0074] The present invention also provides an engineered strain which can be used for fermentation production of erythromycin and simultaneously eliminates the emission of the odorous compounds geosmin and / or 2-methylisoborneol.

[0075] In a preferred embodiment, an engineered strain of Saccharopolyspora erythraea D3187-4907-3977 for eliminating geosmin emissions is provided.

[0076] In another preferred embodiment, an engineered strain of Saccharopolyspora erythraea D3722 that eliminates 2-methylisoborneol emission is provided.

[0077] In another preferred embodiment, an engineered strain of Saccharopolyspora erythraea D3187-4907-3977-3722 for eliminating geosmin and 2-methylisoborneol emissions is provided. The engineered strain Saccharopolyspora erythraea D3187-4907-3977-3722 was deposited in the General Microbiological Center (CGMCC) of the China Microbiological Culture Collection Administration (Beijing, China) on April 17, 2023, with a deposit number of CGMCC No: 27128.

[0078] In another preferred embodiment, an engineered strain of Saccharopolyspora erythraea E3D3187-4907-3977-3722 for eliminating geosmin and 2-methylisoborneol emissions is provided.

[0079] Erythromycin

[0080] Erythromycins are a class of 14-membered macrolide antibiotics, which are composed of erythronolide, L-mycarose and D-desosamine connected by glycosidic bonds. Erythromycin is mainly derived from Saccharopolyspora erythraea, has good anti-Gram-positive bacterial activity, and can treat a variety of infectious diseases; at the same time, it has low gastrointestinal toxicity and fewer allergic reactions. Erythromycin antibiotics have a huge market size. The first generation of erythromycin represented by erythromycin A is produced by fermentation of Saccharopolyspora erythraea, while the second and third generation erythromycins such as roxithromycin and azithromycin are mainly produced by chemical synthesis using erythromycin A as a precursor.

[0081] Geosmin synthase

[0082] In the present invention, the term "geosin synthase" refers to a terpene cyclase that can catalyze the cyclization, deacetonization and hydration of the sesquiterpene precursor farnesyl pyrophosphate (FPP) to obtain geosin. Figure 1 By comparing the sequence homology with the genes encoding known geosmin synthases (GeneBank: WP_011030632.1, WP_010983603.1) in the genome of Streptomyces coelicolor (GeneBank: AL645882.2) and Streptomyces avermitilis (GeneBank: BA000030.4), three genes SACE_3187, SACE_4907 and SACE_3977 that may be responsible for encoding geosmin synthase in the genome of Saccharopolyspora erythrae were located.

[0083] The present invention unexpectedly discovered for the first time that the production of geosmin can be blocked by simultaneously knocking out the SACE_3187, SACE_4907 and SACE_3977 genes encoding geosmin synthase in the genome of Saccharopolyspora erythraea.

[0084] 2-Methylisoborneol synthase

[0085] In the present invention, the term "2-methylisoborneol synthase" refers to a terpene cyclase that can catalyze the cyclization reaction of the methylated monoterpene precursor geranyl pyrophosphate (GPP) to obtain 2-methylisoborneol. Figure 1By comparing the sequence homology with the gene encoding the known 2-methylisoborneol synthase (GeneBank: WP_011031839.1) in the genome of Streptomyces coelicolor (GeneBank: AL645882.2), a gene SACE_3722 that may be responsible for encoding 2-methylisoborneol synthase in the genome of Saccharopolyspora erythrae was located.

[0086] The present invention unexpectedly discovered for the first time that knocking out the SACE_3722 gene encoding 2-methylisoborneol synthase in the genome of Saccharopolyspora erythraea can block the production of 2-methylisoborneol.

[0087] Primers

[0088] As used herein, the term "primer" refers to a general term for an oligonucleotide that is paired with a template and can be used as a starting point to synthesize a DNA chain complementary to the template under the action of a DNA polymerase. The primer can be natural RNA, DNA, or any form of natural nucleotides, or even non-natural nucleotides, such as LNA, ZNA, etc.

[0089] A primer is "substantially" (or "essentially") complementary to a particular sequence on the template. A primer must be fully complementary to the sequence of the template to begin extension, but the sequence of the primer does not have to be completely complementary to the sequence of the template. For example, a primer whose 3' end is complementary to the template is added to the 5' end of a sequence that is not complementary to the template. Such a primer is still substantially complementary to the template. As long as there is a primer long enough to fully bind to the template, a primer that is not completely complementary can also form a primer-template complex with the template, thereby amplifying.

[0090] Fermentation production of erythromycin

[0091] The engineered strain of the present invention and the engineered strain constructed by the genetic modification method of the present invention can be used to ferment and produce erythromycin and its derivatives. In a preferred embodiment, the culture medium may include (but is not limited to), except that v / v represents volume percentage, in terms of mass percentage of the culture medium:

[0092] Slant culture medium: corn steep liquor 1.0%, starch 1.0%, NaCl 0.3%, (NH4)2SO4 0.3%, CaCO3 0.5%, agar 2.0%, pH 7.0.

[0093] Seed culture medium: starch 5.0%, soybean cake powder 1.8%, corn steep liquor 1.3%, NaCl 0.3%, (NH4)2SO4 0.1%, NH4NO3 0.1%, CaCO3 0.6%, soybean oil (v / v) 0.5%, pH 6.8-7.0.

[0094] Shake flask fermentation medium: starch 3.0%, soybean cake powder 3.0%, dextrin 4.0%, (NH4)2SO4 0.2%, CaCO3 0.6%, soybean oil (v / v) 1.0%, n-propanol (v / v) 1.0% (added after 24h of fermentation), pH 7.0-7.2.

[0095] Homologous recombination

[0096] Homologous recombination refers to the recombination between sister chromatids or between or within DNA molecules containing homologous sequences on the same chromosome. Homologous recombination requires a series of protein catalysis, such as RecA, RecBCD, RecF, RecO, RecR, etc. in prokaryotic cells; and Rad51, Mre11-Rad50, etc. in eukaryotic cells.

[0097] Homologous recombination can be used for gene knockout, specifically, including two ways of insertion inactivation and in-frame deletion. In the present invention, insertion inactivation refers to connecting the DNA fragment in the target gene with a vector containing a selection marker gene (such as an antibiotic resistance gene) to construct an insertion inactivation plasmid, which is introduced into the recipient bacteria by conjugation transfer and undergoes a homologous recombination, so that the linearized plasmid is inserted into the target gene and loses its original function; in-frame deletion refers to connecting the left and right homologous arm DNA fragments of the target gene and its upstream and downstream to a vector containing a selection marker gene (such as an antibiotic resistance gene), constructing a in-frame deletion plasmid, which is introduced into the recipient bacteria by conjugation transfer and undergoes two homologous recombinations, so that the base pairs of an integer multiple of 3 are deleted in the target gene, and in the gene translation process, several complete codons are deleted and other codons can be translated normally, so that the generation of polarity effects will not interfere with the functions of upstream and downstream genes.

[0098] CRISPR / Cas9

[0099] CRISPR (Clustered regularly interspaced short palindromic repeats) / Cas9 (CRISPR-associated protein 9) is an immune system that prokaryotes have evolved to resist the invasion of foreign genes such as viruses. After development, CRISPR / Cas9 has become a gene-directed editing technology for specific sites. Its main function is to identify and cut specific DNA fragments mediated by sgRNA (single-guide RNA) containing a targeting sequence. CRISPR / Cas9 cuts DNA to produce double-strand breaks, which usually activate the repair mechanism in the cell, thus greatly improving the efficiency of homologous recombination.

[0100] Engineering strain and preparation method thereof

[0101] The "engineered strain" and "genetically engineered strain" of the present invention can be used interchangeably, both referring to reducing the expression level of endogenous geosmin synthase genes (SACE_3187, SACE_4907 and SACE_3977 genes) and / or 2-methylisoborneol synthase gene (SACE_3722 gene).

[0102] Compared with the starting strain, the engineered strain of the present invention has the function of blocking the production of geosmin and / or 2-methylisoborneol, and at the same time does not affect the fermentation yield and quality of erythromycin.

[0103] The starting strain that can be used for transformation into the engineered strain of the present invention is a strain belonging to the genus Saccharopolyspora, in particular Saccharopolyspora erythrae.

[0104] The engineered strain of the present invention can be obtained by the following method:

[0105] (a1) knocking out endogenous geosmin synthase genes (SACE_3187, SACE_4907 and SACE_3977 genes) and / or 2-methylisoborneol synthase gene (SACE_3722 gene) in host cells;

[0106] (b1) culturing the host cell;

[0107] The host cell is the starting strain.

[0108] Pharmaceutical compositions and modes of administration

[0109] Erythromycin or its derivatives in the engineered strain fermentation product of the present invention can be used to prepare medicines. The compounds of the present invention can be applied to mammals, such as humans, and can be applied orally, rectally, parenterally (intravenously, intramuscularly or subcutaneously), topically, etc. These compounds can be administered alone or in combination with other pharmaceutically acceptable compounds. It should be noted that the compounds of the present invention can be administered in combination.

[0110] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following components: (a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, such as hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic; (c) humectants, such as glycerol; (d) disintegrators, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (e) slow solvents, such as paraffin; (f) absorption promoters, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate or mixtures thereof. In capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0111] Solid dosage forms such as tablets, sugar pills, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be released in a delayed manner in a part of the digestive tract. Examples of embedded components that can be used are polymers and waxy materials. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.

[0112] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs. In addition to the active compound, the liquid dosage form may also contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.

[0113] Besides these inert diluents, the composition may also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents and flavoring agents.

[0114] Suspensions, in addition to the active compounds, may contain suspending agents, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and isosorbide dinitrate, microcrystalline cellulose, aluminum methanol and agar, or mixtures thereof.

[0115] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0116] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, propellants and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers or, if desired, propellants.

[0117] When using a pharmaceutical composition, a safe and effective amount of the compound of the present invention is applied to a mammal (e.g., a human) in need of treatment, wherein the dosage is a pharmaceutically effective dose, and is used for an individual of 60 kg body weight, and the daily dosage is generally 1-1000 mg, preferably 20-500 mg. Of course, the specific dosage should also take into account the route of administration, individual health conditions, and other factors, which are all within the skill range of a skilled physician.

[0118] Strain preservation

[0119] The erythraea Saccharopolyspora erythraea D3187-4907-3977-3722 (the same as the deposited name) of the present invention was deposited in the General Microbiology Center (CGMCC) of the China Microorganism Culture Collection Administration on April 17, 2023, at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, with the deposit number: CGMCC No. 27128.

[0120] The main advantages of the present invention include:

[0121] (1) The present invention first discovered that if the expression level of endogenous geosmin synthase genes (such as the three genes SACE_3187, SACE_4907 and SACE_3977) and / or 2-methylisoborneol synthase genes (such as the SACE_3722 gene) in the starting strain is reduced, the production of geosmin and / or 2-methylisoborneol can be blocked without affecting the erythromycin fermentation yield and quality.

[0122] (2) The present invention locates three geosmin synthase genes SACE_3187, SACE_4907, SACE_3977 and a 2-methylisoborneol synthase gene SACE_3722 in the genome of Saccharopolyspora erythrae through gene sequence comparison, and uses homologous recombination mechanism to construct an engineered strain with the above genes deleted or inactivated in the same frame. It was unexpectedly found that knocking out the three genes SACE_3187, SACE_4907, and SACE_3977 at the same time can block the production of geosmin; knocking out the SACE_3722 gene can block the production of 2-methylisoborneol; knocking out the four genes SACE_3187, SACE_4907, SACE_3977, and SACE_3722 at the same time can block the production of geosmin and 2-methylisoborneol. The series of Saccharopolyspora erythrae engineered strains thus obtained can reduce the emission of odorous compounds without affecting the yield and quality of erythromycin, which helps to control the cost of erythromycin fermentation waste gas treatment.

[0123] (3) The present invention provides a method for reducing the emission of odorous compounds while maintaining the yield and quality of erythromycin fermentation without affecting the erythromycin fermentation yield and quality.

[0124] (4) The present invention blocks the production of geosmin and 2-methylisoborneol from the source by in-frame deletion of the target gene, and the genetic modification of Saccharopolyspora erythrae is directional and irreversible.

[0125] (5) The erythromycin provided by the present invention or the engineered strain constructed based on the genetic modification method of the present invention is applied to the fermentation production of erythromycin, which reduces the emission of odorous compounds and the cost of treating erythromycin fermentation waste gas, thereby generating significant environmental and economic benefits.

[0126] The present invention will be further described below in conjunction with specific embodiment.It should be appreciated that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention.The conditions of the experimental techniques not specifically described in the following examples are usually according to the normal conditions described in Sambrook et al., Molecular Cloning:A Laboratory Manual (New York:Cold Spring Harbor Laboratory Press, 1989), or according to the conditions described in Microbiology Magazine: Laboratory Manual (edited by James Cappuccino and Natalie Sherman of Pearson Education Press) or the conditions recommended by manufacturers.Unless otherwise indicated, percentages and parts are all weight percentages and parts by weight.

[0127] Unless otherwise stated, the materials used in the examples are commercially available products.

[0128] Example 1 Construction of a single gene insertion inactivation engineered strain of Saccharopolyspora erythraea

[0129] 1. Construction of gene insertion inactivation plasmid

[0130] pOJ260 (GenBank: GU270843.1) is a conventional E. coli-actinomycete shuttle vector, containing the apramycin resistance gene aac(3)IV, the E. coli replication origin ori (ColE1) and the element oriT required for conjugative transfer, and is a suicide vector. The vector was linearized using HindIII and EcoRI double restriction enzymes and purified for use.

[0131] Using the total genome of the starting strain as a template, four pairs of specific primers were used to perform PCR amplification to obtain four DNA fragments in the SACE_3187, SACE_4907, SACE_3977, and SACE_3722 genes. The PCR system was double-digested with HindIII and EcoRI, and purified separately for later use.

[0132] The primers required are as follows:

[0133] SACE3187-Sf:CCCC AAGCTT GTCGAGCTGTACAAGCGCAACC(HindIII)

[0134] SACE3187-Sr:CG GAATTC GAACAGGTCGTTGCGCAGGTGCAC(EcoRI)

[0135] The above primer pair was used to amplify a DNA fragment of about 0.4 kb in the SACE_3187 gene.

[0136] SACE4907-Sf:CCCC AAGCTT CTGGAGTACTACAAGCGCACCCG(HindIII)

[0137] SACE4907-Sr:CG GAATTC GAAGATGTCGTTGCGCAGGTGCAC(EcoRI)

[0138] The above primer pair was used to amplify a DNA fragment of about 0.4 kb in the SACE_4907 gene.

[0139] SACE3977-Sf:CCCC AAGCTT CTGGCCCGCTACAAGCGGACC(HindIII)

[0140] SACE3977-Sr:CG GAATTC GAAGATGTCGTTGCGCAGGTG(EcoRI)

[0141] The above primer pair was used to amplify a DNA fragment of about 0.4 kb in the SACE_3977 gene.

[0142] SACE3722-Sf:CCCC AAGCTT ACCAACAGCCGCCGCGACGCCAAC(HindIII)

[0143] SACE3722-Sr:CG GAATTC GTAGAGGGTGGCGATCAGCGTCGC(EcoRI)

[0144] The above primer pair was used to amplify a DNA fragment of about 0.4 kb in length within the SACE_3722 gene.

[0145] The DNA fragment in the target gene and the linearized pOJ260 vector were connected, and the connection system was transformed into conventional Escherichia coli DH5α. The monoclonal colony with apramycin resistance was picked and cultured at 37°C to extract the plasmid. The sequencing results showed that the HindIII and EcoRI restriction sites of the vector pOJ260 were respectively inserted with DNA fragments of about 0.4 kb in the SACE_3187, SACE_4907, SACE_3977, and SACE_3722 genes, thereby obtaining four plasmids pOJ260-S3187, pOJ260-S4907, pOJ260-S3977, and pOJ260-S3722 for insertion inactivation of the target gene.

[0146] The plasmid map used for insertional inactivation of the target gene is as follows Figure 2 shown.

[0147] 2. Construction and screening of engineered strains with single gene insertion inactivation

[0148] The verified plasmids pOJ260-S3187, pOJ260-S4907, pOJ260-S3977, and pOJ260-S3722 were transformed into conventional methylation-deficient Escherichia coli ET12567 (see US7,326,782 and US7,105,491), and the plasmids were introduced into the starting strain NRRL 2338 by conjugation transfer. The conjugants with apramycin resistance were selected and cultured at 30°C.

[0149] In this example, four engineered strains of Saccharopolyspora erythrae with single gene insertion inactivation were successfully constructed by the above method, and they were named S3187, S4907, S3977, and S3722. The construction strategy of the above engineered strains is described using S3187 as an example. Figure 3 shown.

[0150] Example 2 Construction of a single gene in-frame deletion engineered strain of Saccharopolyspora erythraea

[0151] 1. Construction of gene in-frame deletion plasmid

[0152] pOJ260 was linearized by double digestion with HindIII and EcoRI and then purified for later use.

[0153] Using the total genome of the starting strain as a template, eight pairs of specific primers were used for PCR amplification to obtain eight DNA fragments of the left and right homologous arms of the SACE_3187, SACE_4907, SACE_3977, and SACE_3722 genes. The PCR system used to amplify the left arm was double-digested with HindIII and XbaI, and the PCR system used to amplify the right arm was double-digested with XbaI and EcoRI, and purified separately for later use.

[0154] The primers required are as follows:

[0155] SACE3187-Lf:CCCC AAGCTT ATCGGGCTCGCCGCGGGACTC(HindIII)

[0156] SACE3187-Lr:GC TCTAGA CGGGAATGCGTCCGGTACAAG(XbaI)

[0157] The above primer pair was used to amplify the left arm DNA fragment of the SACE_3187 gene of about 2.2 kb in length.

[0158] SACE3187-Rf:GC TCTAGA GGCCCACGCCTTGCTGTGCTC(XbaI)

[0159] SACE3187-Rr:CG GAATTC TCGAGACGGTCGAGAAGATGC(EcoRI)

[0160] The above primer pair was used to amplify the right arm DNA fragment of the SACE_3187 gene of about 2.2 kb in length.

[0161] SACE4907-Lf:CCCC AAGCTTCCGCACGGGGGGACATGGCTG(HindI II)

[0162] SACE4907-Lr:GC TCTAGA GGCGCACAACAGCGCGTAGTC(XbaI)

[0163] The above primer pair was used to amplify the DNA fragment of the left arm of the SACE_4907 gene of about 2.2 kb in length.

[0164] SACE4907-Rf:GC TCTAGA GAATGGCATCGCAGATGTGTC(XbaI)

[0165] SACE4907-Rr:CG GAATTC CTCGGCCATGGATACGCATTC(EcoRI)

[0166] The above primer pair was used to amplify the right arm DNA fragment of the SACE_4907 gene of about 2.2 kb in length.

[0167] SACE3977-Lf:CCCC AAGCTT TTCACCCGCCTTCCAGATACC(HindIII)

[0168] SACE3977-Lr:GC TCTAGA ATGCCCATCTCCTCGGCCCAC(XbaI)

[0169] The above primer pair was used to amplify the left arm DNA fragment of the SACE_3977 gene of about 2.2 kb in length.

[0170] SACE3977-Rf:GC TCTAGA CGCCGTCGCCGAGCAGGAGTTG(XbaI)

[0171] SACE3977-Rr:CG GAATTC GCCACCATGGTCTGGCATTCG(EcoRI)

[0172] The above primer pair was used to amplify the right arm DNA fragment of the SACE_3977 gene of about 2.3 kb in length.

[0173] SACE3722-Lf:CCCC AAGCTT AGCGCTCTAGCGTGACAACGG(HindI II)

[0174] SACE3722-Lr:GC TCTAGACTGGAGGAGGCCACCGGACAC(XbaI)

[0175] The above primer pair was used to amplify the DNA fragment of the left arm of the SACE_3722 gene of about 2.2 kb in length.

[0176] SACE3722-Rf:GC TCTAGA CTCGGGGCGCTCGGGCGGTGG(XbaI)

[0177] SACE3722-Rr:CG GAATTC GGTGACAATTCTCAGAATCGC(EcoRI)

[0178] The above primer pair was used to amplify the right arm DNA fragment of the SACE_3722 gene of about 2.2 kb in length.

[0179] The left and right arm DNA fragments of the target gene and the linearized pOJ260 vector were connected by three fragments, and the connection system was transformed into Escherichia coli DH5α. The monoclonal colonies with apramycin resistance were picked and cultured at 37°C to extract the plasmid. The sequencing results showed that the HindIII and EcoRI restriction sites of the vector pOJ260 were respectively inserted with the left and right homologous arm DNA fragments of the SACE_3187, SACE_4907, SACE_3977, and SACE_3722 genes with a length of about 4.4kb, thereby obtaining four plasmids pOJ260-D3187, pOJ260-D4907, pOJ260-D3977, and pOJ260-D3722 for in-frame deletion of the target gene.

[0180] Plasmid map for in-frame deletion of target gene Figure 4 shown.

[0181] 2. Construction and screening of engineered strains with single gene in-frame deletion

[0182] The verified plasmids pOJ260-D3187, pOJ260-D4907, pOJ260-D3977, and pOJ260-D3722 were transformed into Escherichia coli ET12567, and the above plasmids were introduced into the starting strain NRRL2338 by conjugation transfer. The conjugants with apramycin resistance were selected for multiple rounds (6-15 rounds) of 30°C subculture, and monoclonal colonies with loss of apramycin resistance were screened. These monoclonal colonies underwent two homologous recombination, one part of which returned to the genotype of the starting strain, and the other part formed the target genotype. The target genotype was verified by PCR.

[0183] The primers required are as follows:

[0184] SACE3187-f:ACGCTGCCCGCGGTCTTCG

[0185] SACE3187-r:AGCGCCATTCCCTGGTCGCC

[0186] The above primer pair was used to verify the genotype of the engineered strain with the same-frame deletion of the SACE_3187 gene. A portion of the primers were restored to the genotype of the starting strain to obtain a PCR product of about 3.0 kb, and another portion formed the target genotype to obtain a PCR product of about 0.9 kb.

[0187] SACE4907-f:GGTCAGCAAGACCCGCACCAC

[0188] SACE4907-r:TTCCGGTGGCACCACGTACAC

[0189] The above primer pair was used to verify the genotype of the engineered strain with the same-frame deletion of the SACE_4907 gene. A portion of the primers were restored to the genotype of the starting strain to obtain a PCR product of about 2.9 kb in length, and another portion formed the target genotype to obtain a PCR product of about 1.0 kb in length.

[0190] SACE3977-f:GATTCTTCCTGGCCCACCCG

[0191] SACE3977-r:GAACCCGCGGTCACGATCAC

[0192] The above primer pair was used to verify the genotype of the engineered strain with the same-frame deletion of the SACE_3977 gene. A portion of the primers were restored to the genotype of the starting strain to obtain a PCR product of about 3.0 kb, and another portion formed the target genotype to obtain a PCR product of about 1.2 kb.

[0193] SACE3722-f:CCATGAACGACGAGCCGCCC

[0194] SACE3722-r:ACGGCTTTCCTGCGCGAGTG

[0195] The above primer pair was used to verify the genotype of the engineered strain with the same-frame deletion of the SACE_3722 gene. A portion of the primers were restored to the genotype of the starting strain to obtain a PCR product of about 1.8 kb in length, and another portion formed the target genotype to obtain a PCR product of about 1.0 kb in length.

[0196] In this example, four engineering strains with single gene deletions in the same frame of Saccharopolyspora erythraea were successfully constructed by the above method, and they were named D3187, D4907, D3977, and D3722. The construction strategy of the above engineering strains is described using D3187 as an example. Figure 5 shown.

[0197] Example 3 Construction of a multi-gene in-frame deletion engineered strain of Saccharopolyspora erythraea

[0198] 1. Construction of gene in-frame deletion plasmid

[0199] pWHU2653 [Appl. Microbiol. Biotechnol. 2015, 99, 10575] is an E. coli-actinomycete shuttle vector, containing the apramycin resistance gene aac(3)IV and the ampicillin resistance gene AmpR, the E. coli replication origin ori (ColE1), the Streptomyces replicon rep (pIJ101), the element oriT required for conjugative transfer, the cytosine deaminase gene codA (sm), and the codon-optimized cas9 gene from Streptococcus pyogenes related to CRISPR / Cas9, and the insertion region of the target sgRNA. This plasmid uses the CRISPR / Cas9 system to target the target gene for targeted cutting, which can improve the efficiency of homologous recombination and shorten the construction time of multi-gene in-frame deletion engineering strains. The vector is linearized with NheI and XbaI double enzymes and purified for use.

[0200] Using pWHU2653 as a template, three sets of primers consisting of universal primers and specific primers were used for overlapping PCR amplification to obtain three DNA fragments containing sgRNA (single-guide RNA) sequences encoding targeted cutting of SACE_3187, SACE_3977, and SACE_3722 genes. The PCR system was double-digested with NheI and XbaI and purified separately for later use.

[0201] The primers required are as follows:

[0202] WHU2653-f:accaccaccactga gctagc TTCAGACGTG(NheI)

[0203] WHU2653-r:aggatccccgggta tctaga AAAAAAACCC(XbaI)

[0204] The above primer pairs are universal primers for three overlapping PCRs.

[0205] 3187-sgf:ccagcACTTCGCGAGGCTGATGGTGgttttagagctagaaatagc

[0206] 3187-sgr:aaaacCACCATCAGCCTCGCGAAGTgctggatcctaccaaccggc

[0207] The above primer pair is used to amplify a DNA fragment of about 0.3 kb in length, which contains an sgRNA sequence encoding the targeted cleavage of the SACE_3187 gene.

[0208] 3977-sgf:ccagcCTCCGCCGGGAACGGCGTACgttttagagctagaaatagc

[0209] 3977-sgr:aaaacGTACGCCGTTCCCGGCGGAGgctggatcctaccaaccggc

[0210] The above primer pair is used to amplify a DNA fragment of about 0.3 kb in length, which contains an sgRNA sequence encoding the targeted cleavage of the SACE_3977 gene.

[0211] 3722-sgf:ccagcGAACGAGTTCATCTGCCGGTgttttagagctagaaatagc

[0212] 3722-sgr:aaaacACCGGCAGATGAACTCGTTCgctggatcctaccaaccggc

[0213] The above primer pair is used to amplify a DNA fragment of about 0.3 kb in length, which contains an sgRNA sequence encoding the targeted cleavage of the SACE_3722 gene.

[0214] The DNA fragment containing the sgRNA sequence and the linearized pWHU2653 vector were connected, and the connection system was transformed into Escherichia coli DH5α. Monoclonal colonies with apramycin and ampicillin resistance were selected and cultured at 37°C to extract plasmids. Sequencing results showed that the NheI and XbaI restriction sites of the vector pWHU2653 were respectively inserted with DNA fragments of about 0.3 kb in length, thereby obtaining three intermediate plasmids pWHU2653-sg3187, pWHU2653-sg3977, and pWHU2653-sg3722.

[0215] The intermediate plasmids pWHU2653-sg3187, pWHU2653-sg3977, and pWHU2653-sg3722 were linearized by single restriction digestion with HindIII and then purified for later use.

[0216] Plasmids pOJ260-D3187, pOJ260-D3977, and pOJ260-D3722 were used as templates, and three pairs of specific primers were used for PCR amplification to obtain three DNA fragments of the homology arms of the SACE_3187, SACE_3977, and SACE_3722 genes. The PCR systems were purified separately for later use.

[0217] The primers required are as follows:

[0218] 3187-HRf:gacctgcaggcatgc AAGCTT ATCGGGCTCGCCGCGGGACTC(HindIII)

[0219] 3187-HRr:gcttgcggcagcgtg AAGCTT TCGAGACGGTCGAGAAGATGC(HindIII)

[0220] The above primer pair was used to amplify a SACE_3187 gene homology arm DNA fragment of about 4.3 kb.

[0221] 3977-HRf:gacctgcaggcatgc AAGCTT TTCACCCGCCTTCCAGATACC(HindIII)

[0222] 3977-HRr:gcttgcggcagcgtg AAGCTT GCCACCATGGTCTGGCATTCG(HindIII)

[0223] The above primer pair was used to amplify a SACE_3977 gene homology arm DNA fragment of about 4.5 kb.

[0224] 3722-HRf:gcttgcggcagcgtg AAGCTT AGCGCTCTAGCGTGACAACGG(HindIII)

[0225] 3722-HRr:gacctgcaggcatgc AAGCTT GGTGACAATTCTCAGAATCGC(HindIII)

[0226] The above primer pair was used to amplify a SACE_3722 gene homology arm DNA fragment of about 4.3 kb.

[0227] The homology arm DNA fragments of the target gene and the linearized intermediate plasmid were assembled using 5×In-Fusion Enzyme Premix (TAKARA), and the reaction system was transformed into Escherichia coli DH5α. Monoclonal colonies with apramycin and ampicillin resistance were picked and cultured at 37°C to extract plasmids. Sequencing results showed that the HindIII restriction site of the intermediate plasmid was inserted with about 4.4 kb homology arm DNA fragments of SACE_3187, SACE_3977, and SACE_3722 genes, respectively, thus obtaining three plasmids pWHU2653-D3187, pWHU2653-D3977, and pWHU2653-D3722 for in-frame deletion of the target gene.

[0228] Plasmid map containing CRISPR / Cas9 system for multiple gene in-frame deletion Figure 6 shown.

[0229] 2. Construction and screening of engineered strains with double gene deletions

[0230] The verified plasmid pWHU2653-D3187 was transformed into Escherichia coli ET12567, and the plasmid was introduced into the engineering strains D4907 and D3977 respectively by conjugation transfer. The conjugants with apramycin resistance were selected for multiple rounds (2-5 rounds) of 30°C subculture, and monoclonal colonies were screened using a medium containing 5-fluorocytosine. By PCR verification (verification primers refer to Example 2), two double-gene in-frame deletion Saccharopolyspora erythrae engineering strains were obtained, which were named D3187-4907 and D3187-3977 respectively.

[0231] The verified plasmid pWHU2653-D3977 was transformed into Escherichia coli ET12567, and the plasmid was introduced into the engineered strain D4907 by conjugation transfer. The conjugants with apramycin resistance were selected for multiple rounds (2-5 rounds) of 30°C subculture, and monoclonal colonies were screened using a medium containing 5-fluorocytosine. By PCR verification (reference example 2 for verification primers), a double gene in-frame deletion of Saccharopolyspora erythrae engineered strain was obtained, named D4907-3977.

[0232] 3. Construction and screening of engineered strains with three gene deletions

[0233] The verified plasmid pWHU2653-D3977 was transformed into Escherichia coli ET12567, and the plasmid was introduced into the engineered strain D3187-4907 by conjugation transfer. The conjugants with apramycin resistance were selected for multiple rounds (2-5 rounds) of 30°C subculture, and monoclonal colonies were screened using a medium containing 5-fluorocytosine. By PCR verification (verification primers refer to Example 2), a three-gene in-frame deletion of Saccharopolyspora erythrae engineered strain was obtained, named D3187-4907-3977.

[0234] 4. Construction and screening of engineered strains with four-gene in-frame deletion

[0235] The verified plasmid pWHU2653-D3722 was transformed into Escherichia coli ET12567, and the plasmid was introduced into the engineered strain D3187-4907-3977 by conjugation transfer. The conjugants with apramycin resistance were selected for multiple rounds (2-5 rounds) of 30°C subculture, and monoclonal colonies were screened using a medium containing 5-fluorocytosine. By PCR verification (verification primers refer to Example 2), a four-gene in-frame deletion of Saccharopolyspora erythrae engineered strain was obtained, named D3187-4907-3977-3722.

[0236] Referring to the engineering strain construction process of Example 2 and Example 3, the starting strain HL3168 E3 was used to sequentially perform in-frame deletions of the target genes to construct an engineering strain of Saccharopolyspora erythraea with four gene in-frame deletions, named E3D3187-4907-3977-3722.

[0237] In this example, a series of engineering strains with multiple gene deletions in the same frame of Saccharopolyspora erythrae were successfully constructed through the above process. The construction strategy is described using D3187-4907-3977-3722 as an example. Figure 7 shown.

[0238] Example 4 Fermentation of Saccharopolyspora erythraea and product extraction

[0239] The starting strains of Saccharopolyspora erythrae NRRL 2338, HL3168 E3 and the engineered strains D3187-4907-3977-3722 and E3D3187-4907-3977-3722 were cultured on slant medium at 34°C for 7 days to grow spores. Figure 8 As shown in (photo of spore production of strains), the same-frame deletion of the genes encoding geosmin synthase and 2-methylisoborneol synthase did not affect the colony appearance and spore production of Saccharopolyspora erythraea.

[0240] Take 1×1 cm 2The agar block with bacteria was inoculated into 50 ml fermentation seed medium and cultured at 34°C, 250 rpm for 2 days. 5 ml of seed culture solution was transferred to 50 ml fermentation medium and cultured at 34°C, 250 rpm for 6 days, and n-propanol was added 24 hours after inoculation.

[0241] After fermentation is completed, a portion of the fermentation liquid is sealed and preserved for GC-MS / MS detection.

[0242] Another part of the fermentation broth was adjusted to pH 8.9 with NaOH, and the supernatant was collected by centrifugation. An equal volume of n-hexane was added to the supernatant, and the mixture was shaken and mixed, and the lower aqueous phase was collected. The n-hexane layer was washed with water twice, and the lower aqueous phase was collected and combined. Chloroform was added, and the mixture was shaken and mixed. The lower organic phase was collected by centrifugation, and the chloroform was rotary evaporated to obtain a fermentation crude extract. The crude extract was dissolved in methanol and used for HPLC detection.

[0243] Example 5 Olfactory experiment of erythrocyte fermentation product

[0244] Combined with the smell method, 10 laboratory personnel who are familiar with the smell of actinomycetes were selected to conduct olfactory experiments on the fermentation broth of the starting strain NRRL 2338 and the engineered strains D3187-4907-3977, D3722, and D3187-4907-3977-3722. After shuffling the labels of the fermentation broths of each strain, 10 laboratory personnel were asked to evaluate whether each sample had an earthy smell, a musty smell, and whether the smell was acceptable by smelling. The results of the olfactory experiment are shown in Table 1. It can be found that knocking out the coding genes of geosmin synthase and 2-methylisoborneol synthase can significantly improve the odor of the fermentation broth of the relevant engineered strains.

[0245]

[0246] Example 6 GC-MS / MS Detection of Geosmin and 2-Methylisoborneol in Fermentation Products of Saccharopolyspora erythraea

[0247] A GC-MS / MS detection and analysis method was established by using a mixed standard of geosmin and 2-methylisoborneol (SIGMA) dissolved in pure water to make a 1 mg / L mother solution and then micro-injected. This method can sensitively and accurately detect geosmin and 2-methylisoborneol, with a detection limit of ng / L level. Using this method, the retention times of geosmin and 2-methylisoborneol were 14.2 min and 11.0 min, respectively, and the mass-to-charge ratios (m / z) of the parent ions after molecular fragmentation were 112 and 95, respectively.

[0248] The fermentation broth of the starting strain NRRL 2338 was used for GC-MS / MS detection. The results are as follows Fig. 9(Including TIC chromatogram and EIC chromatogram). The ion flow of the parent ions after the fragmentation of geosmin and 2-methylisoborneol molecules was extracted, and it was found that the starting strain was able to ferment and produce geosmin and 2-methylisoborneol.

[0249] The fermentation broth headspace of single gene knockout engineering strains S3187, D3187, S4907, D4907, S3977, D3977, S3722, and D3722 was enriched and sampled for GC-MS / MS detection. The results are as follows Fig.10 (Including the EIC chromatogram with an extracted mass-to-charge ratio of 112). By extracting the ion flow of the parent ion after the geosmin molecule was fragmented, it was found that knocking out any one of the geosmin synthase genes alone could not block the production of geosmin.

[0250] The fermentation broth headspace of single gene knockout engineering strains D3187, D4907, D3977, S3722, and D3722 was enriched and sampled for GC-MS / MS detection. The results are as follows Fig.11 (Contains an EIC chromatogram with an extracted mass-to-charge ratio of 95). By extracting the ion current of the parent ion after the fragmentation of the 2-methylisoborneol molecule, it can be found that both insertion inactivation and in-frame deletion of the 2-methylisoborneol synthase gene SACE_3722 can block the production of 2-methylisoborneol.

[0251] The fermentation broth headspace of the double gene knockout engineering strains D3187-4907, D3187-3977, and D4907-3977 was enriched and sampled for GC-MS / MS detection. The results are as follows Fig.12 (Contains EIC chromatogram with extracted mass-to-charge ratio of 112, ii ii). The fermentation broth headspace of triple-gene knockout engineering strain D3187-4907-3977 and quadruple-gene knockout engineering strains D3187-4907-3977-3722 and E3D3187-4907-3977-3722 was enriched and sampled for GC-MS / MS detection. The results are as follows Fig.12 (Contains EIC chromatograms with an extracted mass-to-charge ratio of 112, iv-vi). By extracting the ion flow of the parent ion after the geosmin molecule was fragmented, it was found that knocking out any two geosmin synthase genes could not block the production of geosmin, while knocking out three geosmin synthase genes at the same time could block the production of geosmin.

[0252] Example 7 HPLC Detection of Erythromycin A from Saccharopolyspora erythraea Fermentation Product

[0253] The HPLC detection of Saccharopolyspora erythraea fermentation broth was performed using a Luna 5u CN 100R (250, 4.6 mm) chromatographic column, mobile phase: 55% A phase (H2O 32mM K2HPO4), B phase (CH3CN∶CH3OH 80:20), flow rate 1 mL / min, UV detection wavelength 215 nm.

[0254] The crude fermentation extracts of the starting strain NRRL 2338 and its derived engineered strain D3187-4907-3977-3722 after parallel fermentation were subjected to HPLC detection, and the results are shown in Table 2. It can be found that the in-frame deletion of the coding genes of geosmin synthase and 2-methylisoborneol synthase does not affect the yield and proportion of erythromycin A in the NRRL 2338 related strains.

[0255]

[0256] The crude fermentation extracts of the starting strain HL3168 E3 and its derived engineered strain E3D3187-4907-3977-3722 after parallel fermentation were tested by HPLC, and the results are shown in Table 3. It can be found that the in-frame deletion of the coding genes of geosmin synthase and 2-methylisoborneol synthase does not affect the yield and proportion of erythromycin A in HL3168 E3 related strains.

[0257]

[0258]

[0259] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A genetically engineered strain for blocking the production of geosmin and / or 2-methylisoborneol, characterized in that: The expression level of endogenous geosmin synthase gene and / or 2-methylisoborneol synthase gene in the engineered strain is reduced, the geosmin synthase gene includes SACE_3187, SACE_4907 and SACE_3977 genes, and the 2-methylisoborneol synthase gene is SACE_3722 gene.

2. The genetically engineered strain according to claim 1, characterized in that The genetically engineered strain is a bacterium of the genus Saccharopolyspora.

3. The genetically engineered strain according to claim 1, characterized in that The genetically engineered strain is a derivative strain of Saccharopolyspora erythraea NRRL 2238, preferably, Saccharopolyspora erythraea D3187-4907-3977, Saccharopolyspora erythraea D3722 or Saccharopolyspora erythraea D3187-4907-3977-3722.

4. The genetically engineered strain according to claim 1, characterized in that The genetically engineered strain is a derivative strain of Saccharopolyspora erythraea HL3168 E3, preferably, Saccharopolyspora erythraea E3D3187-4907-3977-3722.

5. The genetically engineered strain according to claim 1, characterized in that The sequence of the SACE_3187 gene is shown in SEQ ID NO.

1.

6. The genetically engineered strain according to claim 1, characterized in that The sequence of the SACE_4907 gene is shown in SEQ ID NO.

2.

7. The genetically engineered strain according to claim 1, characterized in that The sequence of the SACE_3977 gene is shown in SEQ ID NO.

3.

8. The genetically engineered strain according to claim 1, characterized in that The sequence of the SACE_3722 gene is shown in SEQ ID NO.

4.

9. A method for constructing the engineered strain according to claim 1, characterized in that: Includes steps: (a) reducing the expression level of endogenous geosmin synthase gene and / or 2-methylisoborneol synthase gene in the starting strain, thereby obtaining the engineered strain according to claim 1, wherein the geosmin synthase gene includes SACE_3187, SACE_4907 and SACE_3977 genes, and the 2-methylisoborneol synthase gene is SACE_3722 gene.

10. A use of the engineered strain according to claim 1, characterized in that: The engineered strain is used as a strain for (i) blocking the production of geosmin and / or 2-methylisoborneol; and (ii) fermenting and producing erythromycin.